title: The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer.
abstract: 5alpha-Reductase type 2, the predominant prostatic isozyme of this protein, converts testosterone to dihydrotestosterone. It has been hypothesized that individuals with greater 5alpha-reductase activity are at increased risk for prostate cancer (CaP). A single nucleotide polymorphism of the 5alpha-reductase type 2 gene (SRD5A2) gives rise to a substitution of leucine (leu) for valine (val) at codon 89 (V89L), the presence of which may affect serum androstanediol glucuronide (AAG) levels. We studied the effect of this polymorphism on the risk of prostate cancer in a prospective, nested, case-control design within the Physicians' Health Study. In all controls (n = 799), the leu allele frequency was 0.30. Among the 386 controls with plasma AAG levels available, there was no significant association between AAG levels and V89L genotype. We also detected no significant association between risk for CaP and genotype [odds ratio: val/val = 1.0 (reference), leu/val = 0.96 (95% confidence interval, 0.76-1.20), and leu/ leu = 0.84 (95% confidence interval, 0.57-1.24)]. These data do not support a moderate to large effect of the SRD5A2 V89L polymorphism on plasma AAG levels or CaP risk in this predominantly Caucasian cohort, although a small effect cannot be completely excluded.
authors.affiliation: Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA.
authors.forename: P G
authors.initials: PG
authors.lastname: Febbo
authors.forename: P W
authors.initials: PW
authors.lastname: Kantoff
authors.forename: E A
authors.initials: EA
authors.lastname: Platz
authors.forename: D
authors.initials: D
authors.lastname: Casey
authors.forename: S
authors.initials: S
authors.lastname: Batter
authors.forename: E
authors.initials: E
authors.lastname: Giovannucci
authors.forename: C H
authors.initials: CH
authors.lastname: Hennekens
authors.forename: M J
authors.initials: MJ
authors.lastname: Stampfer
mesh_terms: D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000235:genetics*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019943:Amino Acid Substitution; D016588:Anticarcinogenic Agents / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001900:Boston / Q000453:epidemiology; D004311:Double-Blind Method; D006331:Heart Diseases / Q000517:prevention & control; D006801:Humans; D007527:Isoenzymes / Q000235:genetics; D007930:Leucine; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000517:prevention & control; D011110:Polymorphism, Genetic; D011471:Prostatic Neoplasms / Q000453:epidemiology* / Q000235:genetics*; D012307:Risk Factors; D014633:Valine; D044465:White People; D019207:beta Carotene / Q000627:therapeutic use
chemical_list: D016588:Anticarcinogenic Agents; D007527:Isoenzymes; D019207:beta Carotene; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase; D007930:Leucine; D014633:Valine; D001241:Aspirin